Anthropic expands Claude's role in drug development with biotech and pharma partners
Reported by TechRadar1 source ↓
Anthropic is working with biotechnology and pharmaceutical companies on drug design, manufacturing and clinical research. TechRadar reports experimental results from several projects, while most treatments remain at early stages.
Key points
- Generate Biomedicines reported shorter CAR T-cell components and increased receptor production after using Claude Code
- Divergence Labs generated about 35,000 antibody designs in a month for a potential food-allergy treatment
- Enveda said Claude cut manual manufacturing-document review time by 89%
- Bristol Myers Squibb and Anthropic are assessing Claude's use in clinical study planning
Details
TechRadar reports that Anthropic is working with drug developers on potential treatments for cancer, food allergies and rare muscular disorders, alongside pharmaceutical manufacturing and clinical research. Most of the treatments discussed remain experimental. Anthropic says direct work with drug programs helps it identify model limitations and areas for improvement.
At Generate Biomedicines, six scientists used Claude Code to redesign a component of CAR T-cell therapy. The component was about 70% shorter, and laboratory experiments found the modified immune cells produced roughly ten times more cancer-detecting receptors; the cells also destroyed cancer cells more effectively and remained active longer, according to the reported findings. Divergence Labs used Claude to produce about 35,000 antibody designs in a month; initial tests found three that bound to IgE and 20 that detached it from immune cells, with three of the latter outperforming a standard medication in those tests.
BigHat Biosciences used Claude with automated laboratory equipment to test about 1,010 antibody-fragment variations over ten weeks. The strongest cancer-targeting version bound its target more than ten times as tightly and remained stable at temperatures 18°C higher than the original; another version aggregated more than 100 times more slowly. Enveda reported that Claude identified all 11 previously found issues in a 1,061-page manufacturing review and seven additional issues, reducing manual checking time by 89%, from more than 25 hours to under three.
Anthropic and Bristol Myers Squibb are assessing Claude's use in evaluating clinical study plans and estimating their chances of success. The companies plan to examine its potential role in decisions during early clinical development. Anthropic says it intends to expand its work with life-science organizations through further partnerships, research programs and tools.
Written from coverage as of
Stocks in this story
Change since open: 20 Nov to 21 Nov 2026
Last refresh